Valuation: Imunon, Inc.

Market Cap 8.98M 7.75M 7.27M 6.62M 12.45M 858M 12.63M 85.24M 33.4M 430M 33.71M 32.98M 1.43B P/E 2026 *
-0.67x
P/E 2027 * -0.86x
Enterprise Value 8.98M 7.75M 7.27M 6.62M 12.45M 858M 12.63M 85.24M 33.4M 430M 33.71M 32.98M 1.43B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day-3.03%
1 week-1.84%
Current month+0.63%
1 month-12.57%
3 months-35.74%
6 months-50.77%
Current year-58.01%
1 week 1.57
Extreme 1.57
1.68
1 month 1.47
Extreme 1.47
2
Current year 1.47
Extreme 1.47
4.2
1 year 1.47
Extreme 1.47
6.96
3 years 1.47
Extreme 1.47
47.61
5 years 1.47
Extreme 1.47
219.13
10 years 1.47
Extreme 1.47
3,834.81
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Date Insider Type Main position Quantity % Market Cap.
03/08/26 Sell

General Counsel

-2,541 0.1008%
31/07/26 Free

Chief Executive Officer

5,010 0.1987%
31/07/26 Free

Director

6,934 0.2750%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-1.84%-75.00%-89.24% 8.98M
+4.80%+3.44%+70.64%+109.32% 73.25B
+17.12%+11.50%+54.42%+87.30% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.42%+5.83%+56.97%+21.50% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+3.80%+5.62%+40.50%-15.26% 19.46B
+3.25%+2.18%+20.86%+554.55% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +2.97%+0.77%+43.05%+171.31% 27.71B
Weighted average by Cap. +5.97%+3.14%+56.18%+163.95%

Financials

2026 *2027 *
Net sales - -
Net income -14.82M -12.8M -12.01M -10.93M -20.56M -1.42B -20.85M -141M -55.15M -710M -55.65M -54.45M -2.36B -19.31M -16.67M -15.64M -14.25M -26.79M -1.85B -27.16M -183M -71.85M -925M -72.5M -70.93M -3.08B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
17/08/26 $1.600 -3.03% 28,141
14/08/26 $1.650 +4.43% 56,770
13/08/26 $1.580 -1.86% 32,769
12/08/26 $1.610 0.00% 27,092
11/08/26 $1.610 -1.23% 54,942
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.600USD
Average target price
17.00USD
Spread / Average Target
+962.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock